Bharat Global (521238)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹174.85 |
| Market Cap | ₹1,863.67 Cr |
| P/E Ratio | 313.87 |
| ROCE | 11.29% |
| ROE | 1.71% |
| Dividend Yield | 0% |
| Profit Growth | -127.34% |
| Debt/Equity | — |
| Sales Growth | -100% |
| 52-Week Range | ₹78.2 — ₹340.3 |
| Sector | IT - Hardware |
| Book Value | ₹19.9 |
Strengths
- Reported ROCE of 11.29% is the only ratio suggesting some capital productivity, if sustained.
- Positive book value of ₹19.90 per share provides a modest asset base.
- The stock trades well below its 52-week high of ₹340.30, leaving room for sentiment-driven recovery.
Concerns
- Sales growth of -100% and latest quarter sales of ₹0 Cr mean the business has no current revenue.
- Profit growth of -127.34%, Piotroski F-Score of 3/9, and FairStock Score of 0/100 point to severe financial stress.
- P/E of 313.87 and P/B of 8.79 assume a dramatic recovery with no evidence of it yet.
- Zero dividend and ROE of 1.71% give shareholders almost no current return.
AI Analysis
Let me apply the same framework I would use for any business. First, what does Bharat Global actually sell? The latest quarter shows sales of ₹0 Cr and a net profit of ₹-0 Cr. Sales growth is -100%, profit growth is -127%. That is not a temporary hiccup; that is a company that has stopped generating revenue. You cannot value a business on hope alone—that is speculation, not investment. The book value is ₹19.90 per share, but I am asked to pay ₹174.85, or 8.79 times book. Meanwhile, return on equity is only 1.71%. For every hundred rupees of equity, the company earns less than two rupees. At that level, any valuation premium is unjustified unless the business is completely rebuilt. The reported ROCE of 11.29% is the only respectable capital-return number, but with no current sales and debt/equity not disclosed, I cannot rely on it. The price-earnings ratio of 313.87 is absurd for a company with shrinking earnings. The Piotroski F-Score of 3/9 tells me the financial health is poor. There is no dividend, so investors get nothing while waiting. The 52-week range, from ₹78.20 to ₹340.30, looks like a speculative vehicle, not a compounding machine. Graham would say price is what you pay, value is what you get. Here the market cap is ₹1,864 Cr, yet there is no visible earning power to support it. This is a turnaround speculation. I would need to see sales resume, positive cash flows, and return on equity move well above the cost of capital before this becomes interesting. At today's price, the margin of safety is absent.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer